Boyd B. Scott

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

20h-index2.3kcitations35works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and osteoporosis research(11), Bone health and treatments(10), Bone Metabolism and Diseases(9), Renin-Angiotensin System Studies(5), Receptor Mechanisms and Signaling(5)

Publications35 total

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
The Lancet Diabetes & Endocrinology·2019· 164 cited
Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)
Bone Abstracts·2016· 1 cited
インスリン様成長因子1受容体(IGF‐1R)の強力,選択性,経口投与性で有効な新しい2‐(ピラゾール‐4‐イルアミノ)ピリミジン阻害剤の発見
Journal of Medicinal Chemistry·2016
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Gastroenterology·2013· 947 cited
Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial
The Journal of Clinical Endocrinology & Metabolism·2013· 59 cited
Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: A head-to-head comparison with alendronate
Bone·2013· 37 cited
High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate
Bone·2013· 35 cited
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate- a randomized placebo-controlled trial
Bone Abstracts·2013· 1 cited
Odanacatib, a selective cathepsin <scp>K</scp> inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers
British Journal of Clinical Pharmacology·2012· 77 citedOpen Access
Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: A study with odanacatib treatment in the ovariectomized adult rhesus monkey
Bone·2012· 29 cited
Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey
Journal of Bone and Mineral Research·2011· 137 cited
Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys
Journal of Bone and Mineral Research·2011· 116 cited
Evaluation of an experimental urodynamic platform to identify treatment effects: A randomized, placebo‐controlled, crossover study in patients with overactive bladder
Neurourology and Urodynamics·2011· 4 citedOpen Access
Structure-Based Design and Synthesis of 1,3-Oxazinan-2-one Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
Journal of Medicinal Chemistry·2011· 40 citedOpen Access
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket
Bioorganic & Medicinal Chemistry Letters·2011· 8 citedOpen Access
Variability of urodynamic parameters in patients with overactive bladder
Neurourology and Urodynamics·2011· 21 cited
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study
Archives of Gerontology and Geriatrics·2010· 63 cited
An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: Physician and patient attitudes and beliefs
BMC Musculoskeletal Disorders·2010· 20 citedOpen Access
Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1
Bioorganic & Medicinal Chemistry Letters·2010· 12 citedOpen Access
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits
Journal of Bone and Mineral Research·2010· 109 cited
page 1 of 2Next →

Frequent Co-authors

Gerard M. McGeehan(9), Richard K. Harrison(8), Yuri Bukhtiyarov(7), Le T. Duong(6), Colin M. Tice(6), Wei Zhao(6), Suresh B. Singh(6), Jennifer Berbaum(6), Reshma Panemangalore(6), Joan Guo(6), David A. Claremon(6), Zhenrong Xu(5), Salvacion Cacatian(5), Brian M. McKeever(5), Zhongren Wu(5), Carolyn DaSilva(4), Maureen Pickarski(4), R. David Simpson(4), Maria Grazia Cappiello(4), Deborah M. Gurner(3)